Skip to main content
SpringerLink
Log in

Neue Impfstoffe

  • Chapter
Infektiologie Aktuelle Aspekte

Part of the book series: Infektiologie Aktuelle Aspekte ((INFEKTIOLOGIE))

  • 41 Accesses

Zusammenfassung

In den letzten zwei Jahrzehnten ermöglichte die rasante Fortentwicklung der Molekularbiologie und Immunologie erhebliche Verbesserungen unserer Kenntnisse über Pathogenese, Erreger-Wirts-Interaktionen und Abwehrmechanismen bei Infektionskrankheiten. Damit wurden auch wesentliche Voraussetzungen für zahlreiche neue Impfstoffentwicklungen geschaffen. Die Anwendung innovativer Technologien (Tabelle 1) läßt in nächster Zeit eine Reihe neuer bzw. verbesserter Impfungen und Kombinationsimpfungen erwarten, von denen einige bereits in fortgeschrittener klinischer Erprobung oder schon in der Zulassung sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Angelakopoulos H, Hohmann EL: Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 68 (2000) 2135–2141

    Article  PubMed  CAS  Google Scholar 

  2. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 338 (1998) 1405–1412

    Article  PubMed  CAS  Google Scholar 

  3. Bhamarapravati N, Sutee Y: Live attenuated tetravalent dengue vaccine. Vaccine 18 (2000) Suppl 2:44–47

    Article  PubMed  CAS  Google Scholar 

  4. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 (2000) 187–195

    Article  PubMed  CAS  Google Scholar 

  5. Black S, Shinefield H, Ray P, et al.: Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: impact on pneumonia, otitis media, and an update on invasive disease-Results of the Northern CaIifornia Kaiser Permanente Efficacy Trial [Abstract 1398]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA 379 (1999)

    Google Scholar 

  6. Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandstrom E, Wahren B: Cellular cytotoxic response induced by DNA vaccination in HIV-I-infected patients. Lancet 351 (1998) 1320–1325

    Article  PubMed  CAS  Google Scholar 

  7. CDR weekly: National enhanced surveillance of suspected meningococcal disease. Communicable Disease Report 47 (2000) 419–420

    Google Scholar 

  8. Churdboonchart V, Sakondhavat C, Kulpradist S, Na Ayudthya BI, Chandeying V, Rugpao S, Boonshuyar C, Sukeepaisarncharoen W, Sirawaraporn W, Carlo DJ, Moss R: A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-I) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected these subjects with CD4-cell counts of >300. Clin Diagn Lab Immunol 7 (2000) 728–733

    PubMed  CAS  Google Scholar 

  9. Clark HF, Glass RI, Offit PA: Rotavirus vaccines. In: Vaccines (Eds.: Plotkin SA, Orenstein OA) WB Saunders, Philadelphia (1999)

    Google Scholar 

  10. Clemens JD, Sack DA, Harris JR, Cha kraborty J, Neogy PK, Stanton B, Huda N, Khan MU, Kay BA, Khan MR, et al Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 158 (1988) 372–377

    Article  PubMed  CAS  Google Scholar 

  11. Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, Rao MR, Khan MR, Yunus M, Huda N, et al: Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335 (1990) 270–273

    Article  PubMed  CAS  Google Scholar 

  12. Coffin SE: Rotavirus vaccines: current controversies and future diections. Curr Infect Dis Rep 2 (2000) 68–72

    Article  PubMed  Google Scholar 

  13. Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I, Shemer J, Taylor DN, Hale TL, Sadoff JC, Pavliakova D, Schneerson R, Robbins JB: Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349 (1997) 155–159

    Article  PubMed  CAS  Google Scholar 

  14. Coster TS, Killeen KP, Waldor MK, Beattie DT, Spriggs DR, Kenner JR, Trofa A, Sadoff JC, Mekalanos JJ, Taylor DN Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae 0139 vaccine prototype. Lancet 345 (1995) 949–952

    Article  PubMed  CAS  Google Scholar 

  15. Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL: Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67 (1999) 3437–3443

    PubMed  CAS  Google Scholar 

  16. De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, Senatore F, Verweij P, Fritzell B, Podda A: Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17 (1999) 3094–3101

    Article  PubMed  Google Scholar 

  17. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL: Safety and immunogenicity of phoP/ phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 18 (1999) 449–459.

    Article  Google Scholar 

  18. Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, Milligan P, Ballou WR, Holland CA, Kester KE, Voss G, Momin P, Greenwood BM, McAdam KP, Cohen J: A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Am J Trop Med Hyg 61 (1999) 865–868

    PubMed  CAS  Google Scholar 

  19. EMEA (European Agency for the Evaluation of Medicinal Products): Hepacare-European Public Assessment Report (EPAR), London 2000, [http://www.eudra.orglhumandocs/HumansIEPAR/Hepacare/ Hepacare.htm]

    Google Scholar 

  20. EMEA (European Agency for the Evaluation of Medicinal Products): Hexavac-European Public Assessment Report (EPAR), London 2000, [http://www.eudra.orglhumandocs/Humans/EPAR/Hexavac/ Hexavac.htm]

    Google Scholar 

  21. EMEA (European Agency for the Evaluation of Medicinal Products): Infanrix Hexa-European Public Assessment Report (EPAR), London 2000, [http://www.eudra.org/humandocs/Humans/EPAR/Infanrixhexa/ Infanrixhexa.htm]

    Google Scholar 

  22. Evans TG, Schiff M, Graves B, Agosti J, Barritt ML, Garner D, Holley JL: The safety and efficacy of GMCSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin Nephrol 54 (2000) 138–142

    PubMed  CAS  Google Scholar 

  23. Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB: Effective vaccine for lassa fever. J Virol 74 (2000) 6777–6783

    Article  PubMed  CAS  Google Scholar 

  24. Glück U, Gebbers JO, Glück R: Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol 73 (1999) 7780–7786

    PubMed  Google Scholar 

  25. Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR: Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 18 (2000) 1763–1772

    Article  PubMed  CAS  Google Scholar 

  26. Gryseels B: Schistosomiasis vaccines: a devils’ advocate view. Parasitol Today 16 (2000) 46–48

    Article  PubMed  CAS  Google Scholar 

  27. Joensuu J, Koskenniemi E, Paug XL, Vesikari T: Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 350 (1997) 1205–1209

    Article  PubMed  CAS  Google Scholar 

  28. Kahn JS: Respiratory syncytial virus vaccine development. Curr Opin Pediatr 12 (2000) 257–262

    Article  PubMed  CAS  Google Scholar 

  29. Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, Yusibov V, Koprowski H, Plucienniczak A, Legocki AB: A plant-derived edible vaccine against hepatitis B virus. FASEB J 13 (1999) 1796–9

    PubMed  CAS  Google Scholar 

  30. Kenner JR, Coster TS, Taylor DN, Trofa AF, Barrera-Oro M, Hyman T, Adams JM, Beattie DT, Killeen KP, Spriggs DR, et al: Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis 172 (1995) 1126–1129

    Article  PubMed  CAS  Google Scholar 

  31. Kilpi T, Jokinen J, Herra E, et al. Effect of heptavalent pneumococcal conjugate vaccine (PNCCRM) on pneumococcal acute otitis media (AOM) by serotype [Abstract 020]. 2nd International Symposium on Pneumococci and Pneumococcal Diseases, Sun City, South Africa, 2000.

    Google Scholar 

  32. Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Barry EM, Levine MM: Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun 68 (2000) 1034–1039

    Article  PubMed  CAS  Google Scholar 

  33. Levine MM, Kaper JB, Herrington D, Ketley J, Losonsky G, Tacket CO, Tall B, Cryz S: Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 100-HgR. Lancet 2 (1988) 467–470

    Article  PubMed  CAS  Google Scholar 

  34. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB: First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178 (1998) 92–100

    Article  PubMed  CAS  Google Scholar 

  35. Maiwald H, Nothdurft HD, Pröll S, Collard F, Sänger R, Vollmar J, von Sonnenburg F: Gleichzeitige Immunisierung gegen Typhus, Hepatitis A und B: Immunogenität bei Mischung des Typhusimpfstoffs mit dem Hepatitis AlB Kombinationsimpfstoff in einer Injektion. [Abstract Sy 17.3] 5. Deutscher Kongress für Infektions-und Tropenmedizin, München (1999)

    Google Scholar 

  36. Mallet E, Fabre P, Pines E, Salomon H, Staub T, Schodel F, Mendelman P, Hessel L, Chryssomalis G, Vidor E, Hoffenbach A: Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Hexavalent Vaccine Trial Study Group. Pediatr Infect Dis J 19 (2000) 1119–1127

    Article  PubMed  CAS  Google Scholar 

  37. Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, Herranz M, Saldinger PF, CorthesyTheulaz I, Losonsky G, Nichols R, Simon J, Stolte M, Ackerman S, Monath TP, Blum AL: Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116 (1999) 804–812.

    Article  PubMed  CAS  Google Scholar 

  38. MMWR: Withdrawal of Rotavirus Vaccine Recommendation. MMWR 48 (1999) 1007

    Google Scholar 

  39. MMWR: Preventing Pneumococcal Disease Among Infants and Young Children Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 49, RR09 (2000) 1–38

    Google Scholar 

  40. Peltola H, Siitonen A, Kyronseppa H, Simula I, Mattila L, Oksanen P, Kataja MJ, Cadoz M: Prevention of travellers’ diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 338 (1991) 1285–1289

    Article  PubMed  CAS  Google Scholar 

  41. Perez-Schael I, Guntinas MJ, Perez M, Pagone V, Rojas AM, Gonzalez R, Cunto W, Hoshino Y, Kapikian AZ: Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 337 (1997) 1181–1187

    Article  PubMed  CAS  Google Scholar 

  42. Peters BS: HIV immunotherapeutic vaccines. Antivir Chem Chemother 11 (2000) 311–320

    PubMed  CAS  Google Scholar 

  43. Reuman PD, Sawyer MH, Kuter BJ, Matthews Hand The MMRV Study Group: Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. Pediatr Infect Dis J 16 (1997) 662–667

    Article  PubMed  CAS  Google Scholar 

  44. Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, Lesmana MM, Wangsasaputra FF, Pandam SS, Levine MM, O’Hanley PP, Cryz SJ, Simanjuntak CH: Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18 (2000) 2399–2410

    Article  PubMed  CAS  Google Scholar 

  45. Richter LJ, Thanavala Y, Arntzen CJ, Mason HS: Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 18 (2000) 1167–1171

    Article  PubMed  CAS  Google Scholar 

  46. Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speiler S, Culp J, Burkholder JK, Swain WF, Dixon RM, Widera G, Vessey R, King A, Ogg G, Gallimore A, Haynes JR, Heydenburg Fuller D: Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19 (2000) 764–778

    Article  PubMed  CAS  Google Scholar 

  47. Sabchareon A Lang J Chanthavanich P Yoksan S Forrat R Attanath P Sirivichayakul C Pengsaa K Pojjaroen-Anant C Chokejindachai W Jagsudee A Saluzzo JF Bhamarapravati N: Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in thai adults volunteers. Abstract No. 1840,49th; Annual Meeting of th American Society of Tropical Medicine and Hygiene, 2000

    Google Scholar 

  48. Scerpella EG, Sanchez JL, Mathewson III JJ, Torres-Cordero JV, Sadoff JC, Svennerholm AM, DuPont HL, Taylor DN, Ericsson CD: Safety, Immunogenicity, and Protective Efficacy of the Whole-Cell/Recombinant B Subunit (We/rBS) Oral Cholera Vaccine Against Travelers’ Diarrhea. J Travel Med 2 (1995) 22–27

    Article  PubMed  Google Scholar 

  49. Schmitt HJ, Knuf M, Ortiz E, Sanger R, Uwamwezi MC, Kaufhold A: Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 137 (2000) 304–312

    Article  PubMed  CAS  Google Scholar 

  50. Scott DA: Vaccines against Campylobacter jejuni. J Infect Dis 176 (1997) Suppl 2:S183–188

    Article  PubMed  Google Scholar 

  51. Steere AC, Sikand VK, Meurice F, et al.: Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 339 (1998) 209–215.

    Article  PubMed  CAS  Google Scholar 

  52. Stevenson P: Nepal calls the shots in hepatitis E virus vaccine trial. Lancet 355 (2000) 1623

    Article  PubMed  CAS  Google Scholar 

  53. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M: A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 (1997) 86–91

    Article  PubMed  CAS  Google Scholar 

  54. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ: Development of a preventive vaccine for Ebola virus infection in primates. Nature 408 (2000) 605–609

    Article  PubMed  CAS  Google Scholar 

  55. Tacket CO, Losonsky G, Nataro JP, Comstock L, Michalski J, Edelman R, Kaper JE, Levine MM Initial clinical studies of CVD 112 Vibrio cholerae 0139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis 172 (1995) 883–886

    Article  PubMed  CAS  Google Scholar 

  56. Tacket CO, Kotloff KL, Losonsky G, Nataro JP, Michalski J, Kaper JB, Edelman R, Levine MM: Volunteer studies investigating the safety and efficacy of live oral EI Tor Vibrio cholerae O1 vaccine strain CVD 111. Am J Trop Med Hyg 56 (1997) 533–537

    PubMed  CAS  Google Scholar 

  57. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, Edelman R, Kaper JE, Cryz SJ, Giannella RA, Schiff G, Levine MM: Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae 01 EI tor inaba three months after vaccination. Infect Immun 67 (1999) 6341–6345

    PubMed  CAS  Google Scholar 

  58. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R: Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999 Jul 16; 17(22):2826–9

    Google Scholar 

  59. Taylor DN, Cardenas V, Sanchez JL, Begue RE, Gilman R, Bautista C, Perez J, Puga R, Gaillour A, Meza R, Echeverria P, Sadoff J: Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J Infect Dis 181 (2000) 1667–1673

    Article  PubMed  CAS  Google Scholar 

  60. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, Wittes J, Bryant M: Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (HI Nl), A (H3N2), and B viruses. Vaccine 18 (1999) 899–906

    Article  PubMed  CAS  Google Scholar 

  61. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss WR, Sedegah M, de Taisne C, Norman JA, Hoffman SL: Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 (1998) 476–480

    Article  PubMed  CAS  Google Scholar 

  62. White CJ, Stinson D, Staehle B, Cho I, Matthews H, Ngai A, Keller P, Eiden J, Kuter B: and The MMRV Study Group: Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Clin Infect Dis 24 (1997) 925–931

    Article  PubMed  CAS  Google Scholar 

  63. Wiedermann G, Kollaritsch H, Kundi M, Svennerholm AM, Bjare U: Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers’ diarrhea (preliminary report). J Travel Med 7 (2000) 27–29

    Article  PubMed  CAS  Google Scholar 

  64. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe Jr JE, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR: Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 182 (2000) 1331–1342

    Article  PubMed  CAS  Google Scholar 

  65. Yap I, Chan SH: A new pre-S containing recombinant hepatitis B vaccine and its effect on non-responders: a preliminary observation. Ann Acad Med Singapore 25 (1996) 120–122

    PubMed  CAS  Google Scholar 

  66. Zuckerman JN: Hepatitis B third-generation vaccines: improved response and conventional vaccine nonresponse— third generation pre-S/S vaccines overcome non-response. J Viral Hepat 5 (1998) Suppl 2: 13–15

    Article  PubMed  Google Scholar 

Download references

Authors
  1. T. Löscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Hölscher
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Donauspital im SMZ-Ost, A-1220, Langobardenstraße 122, Wien, Austria

    Oskar Janata (Facharzt für Innere Medizin, Hygienebeauftragter Arzt) (Facharzt für Innere Medizin, Hygienebeauftragter Arzt)

  2. Med. Chem. Labordiagnostik u. Tropenmedizin, Abt. f. Infektiologie u. Tropenmedizin, Universitätsklinik für Innere Medizin, Ernst-Heydemannstraße 6, D-18057, Rostock, Germany

    Emil C. Reisinger (Facharzt für Innere Medizin) (Facharzt für Innere Medizin)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Wien

About this chapter

Cite this chapter

Löscher, T., Hölscher, M. (2001). Neue Impfstoffe. In: Janata, O., Reisinger, E.C. (eds) Infektiologie Aktuelle Aspekte. Infektiologie Aktuelle Aspekte. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6236-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6236-1_20

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83662-0

  • Online ISBN: 978-3-7091-6236-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation